Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

NetraMark Holdings Inc C.AIAI

Alternate Symbol(s):  AINMF

NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.


CSE:AIAI - Post by User

Post by StockHawk1on Nov 30, 2021 6:27pm
124 Views
Post# 34182633

$MEND partners with an Oxford University Company

$MEND partners with an Oxford University Company

Nurosene Health Inc. ( $MEND.C $MNNDF ) is a mental and physical health app and tech company that has a strong scientific and AI focus.


Today $MEND announced that it has partnered with Ni2o (an Oxford University  company)


Ni2o will use Nurosene's NetraAI to support and accelerate research into neurodegenerative disease treatments by using NertaAI's patient maps and computational power in their brain implants. 


Ni2o's implants are able to help damaged brain tissue using light and electrical impulses. 


NetraAI can uncover precise insights about diseases like Alzheimer's, Parkinson's, and ALS through self-generating AI tech. 


Full news here: 

https://www.bloomberg.com/press-releases/2021-11-29/nurosene-partners-with-brain-computer-interface-technology-ni2o-to-pioneer-research-for-alzheimer-s-and-als

 
<< Previous
Bullboard Posts
Next >>